Nektar Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1990-01-01
- Employees
- 137
- Market Cap
- $230M
- Website
- http://www.nektar.com
- Introduction
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.
A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 291
- Registration Number
- NCT04433585
- Locations
- 🇺🇸
University of California - San Diego, La Jolla, California, United States
🇺🇸Desert Medical Advances, Palm Desert, California, United States
🇺🇸Stanford University Hospital, Stanford, California, United States
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
- Conditions
- MelanomaMelanoma (Skin)Melanoma Stage IIIMelanoma Stage IV
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 765
- Registration Number
- NCT04410445
- Locations
- 🇺🇸
Honor Health, Scottsdale, Arizona, United States
🇺🇸Banner MD Anderson Cancer Center, Little Rock, Arkansas, United States
🇺🇸Kaiser Foundation Hospital, Inpatient Pharmacy, Anaheim, California, United States
A Study of NKTR-358 (LY3471851) in Healthy Participants
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 100
- Registration Number
- NCT04380324
- Locations
- 🇺🇸
PRA Health Sciences, Lenexa, Kansas, United States
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
- Conditions
- Multiple MyelomaIndolent Non-Hodgkin LymphomaNon-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT04136756
- Locations
- 🇺🇸
Western Regional Medical Center - CTCA, Goodyear, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
A Study of LY3471851 in Healthy Participants
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT04133116
- Locations
- 🇺🇸
WCCT Global, Cypress, California, United States
A Study of LY3471851 in Participants With Psoriasis
- First Posted Date
- 2019-10-08
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT04119557
- Locations
- 🇺🇸
Arkansas Research Trials, LLC, North Little Rock, Arkansas, United States
🇺🇸California Dermatology & Clinical Research Institute, Encinitas, California, United States
🇺🇸Center For Dermatology Clinical Research, Inc., Fremont, California, United States
A Study of LY3471851 in Participants With Eczema
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 48
- Registration Number
- NCT04081350
- Locations
- 🇺🇸
Arkansas Research Trials, LLC, North Little Rock, Arkansas, United States
🇺🇸California Dermatology & Clinical Research Institute, Encinitas, California, United States
🇺🇸Center For Dermatology Clinical Research, Inc., Fremont, California, United States
A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.
- Conditions
- Moderate to Severe Chronic Pain
- Interventions
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2021-07-08
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 8
- Registration Number
- NCT03802227
- Locations
- 🇺🇸
Investigator Site - Richmond, Richmond, Virginia, United States
A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer
- Conditions
- Urinary Bladder NeoplasmNeoplasm Metastasis
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 192
- Registration Number
- NCT03785925
- Locations
- 🇺🇸
San Francisco VA Medical Center - NAVREF - PPDS, San Francisco, California, United States
🇺🇸Innovative Clinical Research Institute, LLC, Whittier, California, United States
🇺🇸Rocky Mountain Cancer Centers, Aurora, Colorado, United States
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
- Conditions
- Renal Cell CarcinomaMetastatic Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2018-11-02
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 623
- Registration Number
- NCT03729245
- Locations
- 🇺🇸
Alaska Urological, Anchorage, Alaska, United States
🇺🇸Western Regional Medical Center - CTCA - PPDS, Goodyear, Arizona, United States
🇺🇸CARTI Cancer Center, Little Rock, Arkansas, United States